Finzati - Logo
LXRX logo

Lexicon Pharmaceuticals, Inc.

LXRX • Biotechnology
$1.55
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$678.36M
Growth
-8.4%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 186.2%Manageable debt level · 0.58Healthy liquidity · 4.88Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:12 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.55
Change0.00%
Shares Out437.65M
Market Cap$678.36M
Enterprise Value$487.75M
52W Range1.02 - 2.68
Beta1.05
P/E-11.10
P/S16.36
P/B3.89
P/FCF-8.51
EV/Sales11.76

Investment DNA

How strong this company looks for long-term investors

48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
52/100
Why this score▼
Positive revenue growth · 186.2%Manageable debt level · 0.58Healthy liquidity · 4.88Weak profitability

Analyst view

Analyst sentiment and price target

LXRX
Analyst sentiment
Based on 14 analyst votes · 2026-10-20
61/100
Neutral
Bullish
5
Hold
7
Bearish
2
Price Target
2026-08-07
Low
$6.00
Mean
$6.00
Median
$6.00
High
$6.00

Company Overview

IPO: 4/7/2000
Industry: Biotechnology
P/B i: 3.89
Debt / Equity i: 0.58
Operating Margin: -98.21%
Net Margin: -101.08%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.58
Current Ratio: 4.88
Quick Ratio: 4.87
Status: Good

Insider Transactions

Recent executive and insider activity

DEBBANE RAYMOND
Transaction: 06/03/2026
SELL
Change
-89,312
Price
Not reported
Filing
06/04/2026
Type
SELL
DEBBANE RAYMOND
Transaction: 06/03/2026
BUY
Change
+89,312
Price
Not reported
Filing
06/04/2026
Type
BUY
Amouyal Philippe
Transaction: 06/03/2026
SELL
Change
-89,312
Price
Not reported
Filing
06/04/2026
Type
SELL